H.R.1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.113th Congress (2013-2014)
|Sponsor:||Rep. Buchanan, Vern [R-FL-16] (Introduced 03/20/2013)|
|Committees:||House - Energy and Commerce; Judiciary|
|Latest Action:||04/15/2013 Referred to the Subcommittee on Crime, Terrorism, Homeland Security, And Investigations.|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Text: H.R.1285 — 113th Congress (2013-2014)All Bill Information (Except Text)
There is one version of the bill.
Introduced in House (03/20/2013)
Formatting necessary for an accurate reading of this legislative text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF or HTML/XML.
[Congressional Bills 113th Congress] [From the U.S. Government Printing Office] [H.R. 1285 Introduced in House (IH)] 113th CONGRESS 1st Session H. R. 1285 To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 20, 2013 Mr. Buchanan (for himself, Mr. Markey, Mrs. Capito, Mr. Diaz-Balart, Mr. Duncan of Tennessee, Mr. Mica, Mr. Roe of Tennessee, Mr. Rogers of Kentucky, Mr. Rooney, Ms. Ros-Lehtinen, Ms. Brown of Florida, Mr. Cooper, Ms. Edwards, Mr. Hastings of Florida, Mr. Keating, Mr. Lynch, Mr. Rahall, Ms. Wilson of Florida, Mr. Kennedy, Mr. Murphy of Florida, Ms. Castor of Florida, Mr. DesJarlais, Mr. Fincher, Mr. Miller of Florida, Mr. Nugent, Mr. Tiberi, Mr. Issa, Mr. Deutch, Mr. Posey, Mrs. Black, Mr. Pearce, Mr. Marino, Ms. Slaughter, Mr. Westmoreland, Mr. Stivers, Mr. Benishek, Mr. Crenshaw, Mr. Ross, Mr. Higgins, Mr. Southerland, Mr. Tipton, Mr. Shuster, Mrs. Miller of Michigan, Mr. Rodney Davis of Illinois, and Mr. Schock) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. HYDROCODONE AMENDMENT. (a) In General.--Schedule III(d) in section 202 of the Controlled Substances Act (21 U.S.C. 812) is amended by-- (1) striking paragraphs (3) and (4); and (2) redesignating paragraphs (5), (6), (7), and (8) as paragraphs (3), (4), (5), and (6), respectively. (b) Effective Date.--The amendments made by subsection (a) shall take effect on the date that is 6 months after the date of enactment of this Act. SEC. 2. PHYSICAL SECURITY REQUIREMENTS. Notwithstanding the amendments made by section 1, the Attorney General shall immediately, without regard to chapter 5 of title 5, United States Code, amend section 1301.72 of title 21, Code of Federal Regulations, relating to the physical security controls for non- practitioners, narcotic treatment programs and compounders for narcotic treatment programs, and storage areas for controlled substances, to allow, for the 3-year period beginning on the date of enactment of this Act, manufacturers and distributors to store hydrocodone compound products in accordance with the physical security requirements for schedule III, IV, and V controlled substances. SEC. 3. GAO REPORT. (a) In General.--Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall submit to Congress a report on the reclassification of hydrocodone products under this Act. (b) Contents.--The report required under subsection (a) shall include-- (1) an assessment of the degree to which the reclassification of hydrocodone products under this Act impacts the ability of patients with legitimate medical needs, particularly those in rural areas and nursing home facilities, to access adequate pain management; and (2) recommendations necessary to address issues, if any, relating to patient access to adequate pain management. <all>